



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: October 18<sup>th</sup>, 2019*

**Quantity Limit Name:** Rinvoq

**Products Affected:** Rinvoq (Upadacitinib) oral tablets

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

- Rinvoq 15mg tablets: 30 tablets per 30 days

**References:**

1. Rinvoq™ tablets [prescribing information]. North Chicago, IL: AbbVie, Inc.; August 2019.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	10/9/2019

Last Rev. 10/9/2019